Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108070 | 0.86 | BTK (1.00) | BTKJAK2 | |
| SCHEMBL13894285 | 0.76 | BTK (0.61) | BTKJAK2 | |
| SCHEMBL3655731 | 0.71 | BTK (0.54) | BTK | |
| SCHEMBL3655728 | 0.69 | BTK (0.53) | BTK | |
| SCHEMBL12602977 | 0.69 | BTK (0.53) | BTK | |
| SCHEMBL710063 | 0.69 | BTK (0.75) | BTK | |
| SCHEMBL103964 | 0.68 | BTK (0.81) | BTK | |
| SCHEMBL103347 | 0.68 | BTK (0.57) | BTK | |
| SCHEMBL6114249 | 0.68 | BTK (0.68) | BTKJAK2 | |
| SCHEMBL106046 | 0.68 | BTK (0.64) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES (HK) | 2012-05-24 | — | — | US | disclosed |
| US-8124604-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885JAK2 14/4885 |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885JAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.